Drug:
Reaction: DRUG DOSE OMISSION BY DEVICE
20260101 - 20261231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 26482810 |
US |
||
Drug dose omission by device, Device delivery system issue, Product use in unapproved indication, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 402 | 26482811 |
US |
||
Drug dose omission by device, Wrong technique in device usage process, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 403 | 26482812 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Product use issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 404 | 26482813 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 405 | 26482814 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device occlusion, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, |
||||
| 406 | 26482896 |
US |
||
Drug dose omission by device, Device delivery system issue, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 407 | 26482897 |
US |
||
Drug dose omission by device, Device delivery system issue, Wrong technique in device usage process, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 408 | 26482901 |
US |
||
Drug dose omission by device, Device delivery system issue, Device defective, Product tampering, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 409 | 26482906 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 410 | 26482911 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 411 | 26482913 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, Wrong technique in device usage process, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 412 | 26482915 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 413 | 26482916 |
US |
||
Hypersensitivity, Drug dose omission by device, Device delivery system issue, Device leakage, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 414 | 26482920 |
US |
||
Drug dose omission by device, Device delivery system issue, Product tampering, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 415 | 26482923 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 416 | 26482925 |
US |
||
Product use issue, Drug dose omission by device, Device delivery system issue, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 417 | 26482927 |
US |
||
Drug dose omission by device, Product use issue, Device mechanical issue, Device delivery system issue, Device malfunction, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, |
||||
| 418 | 26482929 |
US |
||
Drug dose omission by device, Product use issue, Device delivery system issue, Device breakage, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, FLUTICASONE PROPIONATE, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, |
||||
| 419 | 26482930 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Product use issue, Wrong technique in device usage process, Device delivery system issue, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 420 | 26482932 |
US |
||
Sleep disorder due to a general medical condition, Dyspnoea, Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 421 | 26482937 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, Device issue, Device defective, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 422 | 26482939 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device occlusion, Device delivery system issue, Wrong technique in device usage process, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 423 | 26482940 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 424 | 26482941 |
US |
||
Drug dose omission by device, Device delivery system issue, Device defective, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 425 | 26482987 |
US |
20 | |
Drug delivery system malfunction, Drug dose omission by device, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB, |
||||
| 426 | 26482989 |
US |
24 | |
Injection site haemorrhage, Drug delivery system malfunction, Wrong technique in product usage process, Drug dose omission by device, Accidental exposure to product, Exposure via eye contact, Exposure via skin contact, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, SERTRALINE, |
||||
| 427 | 26482996 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device delivery system issue, Device defective, Device issue, Device use error, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 428 | 26482997 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device occlusion, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 429 | 26482999 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device malfunction, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 430 | 26483009 |
US |
||
Drug dose omission by device, Device delivery system issue, Device failure, Product use in unapproved indication, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 431 | 26483012 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Incorrect dose administered by device, Device delivery system issue, Device difficult to use, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 432 | 26483609 |
US |
75 | |
Dyspnoea, Drug dose omission by device, Product ineffective, Wrong technique in product usage process, Off label use, Device deposit issue, |
||||
ALBUTEROL SULFATE, |
||||
| 433 | 26483885 |
AR |
42 | 2 |
Device failure, Drug dose omission by device, |
||||
ETANERCEPT, |
||||
| 434 | 26484490 |
US |
66 | 2 |
Device difficult to use, Drug dose omission by device, Arthritis, |
||||
ETANERCEPT, |
||||
| 435 | 26484612 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Product use issue, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 436 | 26484671 |
US |
||
Drug effective for unapproved indication, Product use issue, Drug dose omission by device, Device issue, Device delivery system issue, Device occlusion, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 437 | 26484843 |
US |
51 | 2 |
Blood glucose increased, Drug dose omission by device, Device failure, |
||||
INSULIN ASPART, |
||||
| 438 | 26485031 |
US |
2 | |
Device mechanical issue, Drug dose omission by device, Gait disturbance, |
||||
OFATUMUMAB, |
||||
| 439 | 26485105 |
US |
50 | |
Device issue, Drug dose omission by device, |
||||
INFLIXIMAB-DYYB, SEMAGLUTIDE, PROGESTERONE, ESTRADIOL, FOLLICULINUM, OOPHORINUM (SUIS), |
||||
| 440 | 26485199 |
US |
||
Asthma, Wrong technique in product usage process, Device information output issue, Device malfunction, Drug dose omission by device, |
||||
ALBUTEROL SULFATE, |
||||
| 441 | 26476109 |
US |
11 | |
Device malfunction, Drug dose omission by device, Product dose omission issue, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 442 | 26476118 |
US |
||
Device mechanical issue, Device delivery system issue, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 443 | 26476248 |
US |
50 | |
Discomfort, Cough, Drug dose omission by device, Device delivery system issue, Incorrect dose administered by device, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 444 | 26476268 |
US |
1 | |
Needle issue, Device leakage, Drug dose omission by device, Device difficult to use, Accidental exposure to product, |
||||
SECUKINUMAB, |
||||
| 445 | 26476299 |
US |
60 | |
Device malfunction, Drug dose omission by device, Exposure via skin contact, Accidental exposure to product, Product use issue, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 446 | 26476304 |
US |
80 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 447 | 26476320 |
US |
75 | |
Drug dose omission by device, Device malfunction, Exposure via skin contact, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 448 | 26476386 |
US |
44 | |
Drug dose omission by device, Drug delivery system malfunction, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 449 | 26476387 |
US |
47 | |
Dyspnoea, Drug dose omission by device, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 450 | 26476456 |
US |
53 | |
Condition aggravated, Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 451 | 26476475 |
US |
||
Drug delivery system malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 452 | 26476498 |
US |
61 | |
Arthritis, Device malfunction, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 453 | 26476524 |
US |
30 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 454 | 26476587 |
US |
64 | |
Device malfunction, Drug dose omission by device, Therapy interrupted, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, ADALIMUMAB-AATY, ADALIMUMAB-AATY, ADALIMUMAB-AATY, METOPROLOL TARTRATE, METOPROLOL, TRIAMTERENE CAPSULES, TRIAMTERENE, |
||||
| 455 | 26476643 |
US |
35 | |
Device malfunction, Drug dose omission by device, Wrong technique in product usage process, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 456 | 26476783 |
US |
64 | 2 |
Injection site pain, Drug dose omission by device, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 457 | 26476927 |
US |
52 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, AZATHIOPRINE, |
||||
| 458 | 26476969 |
US |
68 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 459 | 26477080 |
CA |
51 | |
Device malfunction, Exposure via skin contact, Accidental exposure to product, Drug dose omission by device, Intentional product use issue, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 460 | 26477105 |
US |
63 | |
Device malfunction, Drug dose omission by device, Wrong technique in product usage process, Intentional product use issue, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, FOLIC ACID, METHOTREXATE, METHOTREXATE SODIUM, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 461 | 26477165 |
US |
2 | |
Psoriatic arthropathy, Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Device delivery system issue, |
||||
SECUKINUMAB, SECUKINUMAB, |
||||
| 462 | 26477558 |
US |
28 | |
Device malfunction, Drug dose omission by device, |
||||
INFLIXIMAB-DYYB, |
||||
| 463 | 26477627 |
US |
39 | |
Device malfunction, Injection site pain, Injection site reaction, Drug dose omission by device, |
||||
INFLIXIMAB-DYYB, CETIRIZINE HYDROCHLORIDE, ERGOCALCIFEROL, |
||||
| 464 | 26477744 |
US |
70 | 2 |
Device difficult to use, Accidental exposure to product, Drug dose omission by device, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 465 | 26477989 |
US |
54 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 466 | 26478158 |
US |
44 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 467 | 26478237 |
US |
52 | |
Device malfunction, Drug delivery system malfunction, Drug dose omission by device, |
||||
INFLIXIMAB-DYYB, |
||||
| 468 | 26478734 |
US |
78 | 1 |
Device difficult to use, Fear of injection, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 469 | 26478788 |
US |
||
Off label use, Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 470 | 26478881 |
US |
23 | |
Device malfunction, Drug dose omission by device, |
||||
INFLIXIMAB-DYYB, |
||||
| 471 | 26478990 |
US |
30 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 472 | 26479135 |
US |
||
Drug dose omission by device, Device delivery system issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 473 | 26479226 |
US |
12 | 2 |
Drug dose omission by device, Device breakage, Device leakage, |
||||
SOMATROPIN, |
||||
| 474 | 26479632 |
US |
8 | 2 |
Drug dose omission by device, Device use error, |
||||
SOMATROPIN, |
||||
| 475 | 26480078 |
US |
15 | |
Device delivery system issue, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 476 | 26480079 |
US |
42 | |
Needle issue, Drug dose omission by device, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, |
||||
| 477 | 26480086 |
US |
62 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 478 | 26480088 |
US |
69 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, LEVOTHYROXINE SODIUM, FOLIC ACID, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 479 | 26480097 |
US |
72 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 480 | 26480117 |
US |
72 | |
Device malfunction, Drug dose omission by device, Product use issue, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 481 | 26480256 |
US |
71 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, |
||||
| 482 | 26480258 |
US |
63 | |
Device malfunction, Drug dose omission by device, |
||||
ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, ADALIMUMAB, ADALIMUMAB-AATY, ADALIMUMAB-ADAZ, ADALIMUMAB-FKJP, METHOTREXATE, METHOTREXATE SODIUM, ZOLEDRONIC ACID, |
||||
| 483 | 26471245 |
US |
76 | 2 |
Injection site pain, Drug dose omission by device, Product dispensing error, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 484 | 26471437 |
US |
81 | 2 |
Fall, Joint dislocation, Ankle fracture, Visual impairment, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 485 | 26471655 |
US |
61 | |
Dyspnoea, Off label use, Drug dose omission by device, Wrong technique in product usage process, Wrong technique in device usage process, Device delivery system issue, Device deposit issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 486 | 26471684 |
GB |
2 | |
Psoriatic arthropathy, Arthralgia, Back pain, Pneumonia, Intervertebral disc compression, Conjunctivitis viral, Hypertension, Drug ineffective, Product use in unapproved indication, Device defective, Accidental exposure to product, Drug dose omission by device, Injection site pain, |
||||
SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, |
||||
| 487 | 26471690 |
US |
||
Drug dose omission by device, Device breakage, Device delivery system issue, Device malfunction, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 488 | 26471696 |
US |
74 | |
Wrong technique in product usage process, Drug dose omission by device, Off label use, |
||||
ALBUTEROL SULFATE, METOPROLOL TARTRATE, METOPROLOL, CLOPIDOGREL, CLOPIDOGREL BISULFATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, TORSEMIDE, ALLOPURINOL, CILOSTAZOL, PANTOPRAZOLE, CALCITRIOL, CALCITRIOL CAPSULES 0.25 MCG, CALCITRIOL CAPSULES 0.5 MCG, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, MONTELUKAST, FISH OIL, VITAMIN C, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, ERGOCALCIFEROL, ZINC, ZINC GLUCONATE, ZINC CHLORIDE, |
||||
| 489 | 26471706 |
US |
52 | |
Wheezing, Drug dose omission by device, Wrong technique in product usage process, Product storage error, |
||||
ALBUTEROL SULFATE, |
||||
| 490 | 26471730 |
US |
57 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, |
||||
| 491 | 26471731 |
US |
62 | 2 |
Drug dose omission by device, Migraine, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 492 | 26471778 |
US |
66 | 1 |
Blood cholesterol increased, Pain, Device difficult to use, Accidental exposure to product, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 493 | 26472257 |
US |
59 | 2 |
Injection site bruising, Wrong technique in product usage process, Drug dose omission by device, Device difficult to use, |
||||
ETANERCEPT, |
||||
| 494 | 26474018 |
US |
72 | 2 |
Knee arthroplasty, Drug dose omission by device, Incorrect route of product administration, Product label confusion, Off label use, Device use error, Device breakage, Device leakage, |
||||
SOMATROPIN, SOMATROPIN, SOMATROPIN, |
||||
| 495 | 26474636 |
US |
30 | 2 |
Migraine, Accidental exposure to product, Drug dose omission by device, |
||||
ERENUMAB-AOOE, ONABOTULINUMTOXINA, |
||||
| 496 | 26474840 |
US |
||
Drug dose omission by device, Product use in unapproved indication, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 497 | 26474843 |
US |
||
Product use in unapproved indication, Drug dose omission by device, Device issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 498 | 26474886 |
US |
||
Device delivery system issue, Drug dose omission by device, Product use in unapproved indication, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 499 | 26474888 |
US |
||
Drug dose omission by device, Device delivery system issue, Product use in unapproved indication, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
| 500 | 26474890 |
US |
||
Product use issue, Drug dose omission by device, Device delivery system issue, |
||||
OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28